Cutaneous Lupus Erythematosus Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Global Cutaneous Lupus Erythematosus Market is segmented By Type (Discoid Lupus Erythematosus (DLE), Subacute Cutaneous Lupus Erythematosus (SCLE), Others), By Drug Class (Topical Corticosteroids, Topical Calcineurin Inhibitors, Oral Antimalarials, Systemic Corticosteroids, Immunosuppressive Medications, Others), By Route of Administration (Oral, Intravenous), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Cutaneous Lupus Erythematosus Market Overview

Global Cutaneous Lupus Erythematosus Market is expected to reach at a High CAGR during the forecast period 2023-2030.

The term "cutaneous lupus erythematosus" (CLE) describes a broad spectrum of dermatological symptoms that may or may not be linked to the emergence of a systemic illness. CLE may be a precursor to systemic lupus erythematosus (SLE). CLE mostly affects the skin, however it can occasionally come before or coexist with SLE, a systemic autoimmune disorder that can affect several organs. Promptly diagnosing and treating CLE may be able to stop or lessen the onset of more serious systemic symptoms.

Since the management and treatment of different skin disorders, including CLE, can differ, dermatologists and other healthcare professionals need to be able to distinguish between them. A correct diagnosis is essential to ensuring the right kind of care. Biologic treatments have been investigated for use in the treatment of CLE. Drugs called biologics are made from live organisms and have the ability to target certain molecules involved in the immune response. The effectiveness of biologics in treating CLE lesions has been studied in some clinical trials.

Cutaneous Lupus Erythematosus Market Scope

For more details on this report - Request for Sample

Cutaneous Lupus Erythematosus Market Dynamics

The Rise of Clinical Studies on CLE

It is increasingly faster to diagnose CLE and differentiate it from other skin disorders due to advancements in diagnostic instruments and methods. This has prompted additional research and clinical trials and led to earlier and more precise diagnosis. There have been improvements made in the treatment of CLE, including as the creation of fresh medications and therapies. Clinical trials are necessary to assess the efficacy and safety of various medicines, which can provide patients with more options. Thus, the rise of clinical trials will accelerate market growth.

For instance, according to LUPUS Foundation 2022, an effective treatment option for persons with cutaneous lupus erythematosus (CLE), a kind of lupus that affects the skin, is belimumab (Benlysta), according to a recent study. This study shows that belimumab medication should not be stopped suddenly because it can produce significant effects after at least 20 weeks of use.

Moreover, October 10, 2022, according to Biogen Inc., the first patient in the international clinical investigation AMETHYST has received a dose. In the Phase 2/3 study, participants with cutaneous lupus erythematosus (CLE) will be compared to placebo to determine the clinical efficacy and safety of litifilimab (also known as BIIB059), a first-in-class humanised IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2). 

A key element is the accessibility of efficient treatment alternatives. Patients have more options as more therapy modalities, such as topical and systemic medicines, become available, fueling market expansion. Patients' capacity to pay for and access care may be impacted by the level of health insurance coverage available for CLE treatments. Treatment demand may rise as a result of broad insurance coverage.

Dynamics: Restraint

There are currently just a few FDA-approved therapies particularly for CLE. Patients may be forced to use off-label or less effective medications as a result of the dearth of available treatment options, which can limit the market's growth. A complex autoimmune condition, CLE has many different subgroups and symptoms. It can be difficult to recognise and treat the various kinds of CLE, which may restrict the advancement of focused therapy.

Cutaneous Lupus Erythematosus Market Segment Analysis

The global cutaneous lupus erythematosus market is segmented based on type, drug class, route of administration, distribution channel and region.

The Discoid Lupus Erythematosus (DLE) Segment From the Type Segment Accounted For Approximately 41.7% of Cutaneous Lupus Erythematosus Share

Discoid Lupus Erythematosus (DLE), commonly referred to as discoid lupus, is an autoimmune illness that manifests as a persistent skin disorder. Skin lesions and rashes are among the most common symptoms of DLE, which mostly affects the skin. It differs from systemic lupus erythematosus (SLE), which can impact several body systems and organs. 

Improved understanding and diagnosis of DLE are important contributing factors. Healthcare personnel are more able to recognise and diagnose autoimmune disorders like DLE as medical understanding and diagnostic methods progress. This might result in more accurate reporting and a seemingly higher number of cases. DLE can develop and worsen due to environmental causes such pollution, exposure to UV radiation from the sun, and other environmental triggers. There may be a higher prevalence of the illness in some areas due to environmental changes or increased exposure to these variables.

Cutaneous Lupus Erythematosus Market Geographical Share

Rising Product Approvals and Product Launches in the North America Region

Due to rising lupus erythematosus awareness, improved healthcare infrastructure, and an increasing number of foundations and independent venture groups supporting biopharmaceutical manufacturers, North America is expected to make up for an important part of the global market for this disease. 

Moreover, CLE and other forms of lupus can occur due to genetic susceptibility. In people with lupus, specific genetic markers and variants are more frequently discovered. Various incidence rates may be influenced by the genetic makeup of the US population, which is made up of people from many different ethnic backgrounds. The condition of CLE is reported to be worse by sunlight exposure. If people in the United States do not effectively protect their skin from UV radiation, especially in areas with high sun exposure, they may be more likely to get CLE.

COVID-19 Impact Analysis

The pandemic disrupted healthcare systems worldwide, leading to postponed or canceled medical appointments, including those for CLE patients. Delayed diagnosis and treatment can worsen CLE symptoms and outcomes. Supply chain disruptions and healthcare resource allocation during the pandemic may have led to interruptions in the availability of medications and treatments for CLE patients. This can impact disease management. To mitigate the risk of exposure to COVID-19, many healthcare providers adopted telemedicine. While this allowed some CLE patients to access care remotely, it may not have been as effective for dermatological conditions that require in-person examinations.

Cutaneous Lupus Erythematosus Market Companies

The major global players in the market include AstraZeneca, AbbVie Inc, ImmuPharma PLC, Biogen Inc, Eli Lilly and Company, Novartis AG, GlaxoSmithKline Inc, Viatris Inc, Pfizer Inc, Bristol-Myers Squibb and among others.

Key Developments

• In October 2022, Biogen Inc. reported that the first patient dosed in the global clinical study, AMETHYST. In the Phase 2/3 study, participants with cutaneous lupus erythematosus (CLE) will be compared to placebo to determine the clinical efficacy and safety of litifilimab (also known as BIIB059), a first-in-class humanized IgG1 monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2). AMETHYST plans to enroll 474 persons with CLE at about 238 venues throughout the world.
• Merck KGaA's M-5049 is undergoing an investigator-sponsored Phase II trial, with results also anticipated in the first half of 2023. There are numerous CLE trials currently underway, ranging from phase 1 through 3 trials. These trials demonstrate efficacy in the skin using the CLASI [Cutaneous Lupus Erythematosus Disease Area and Severity Index] activity score. 

Why Purchase the Report?

• To visualize the global cutaneous lupus erythematosus market segmentation based on type, drug class, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of cutaneous lupus erythematosus market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global cutaneous lupus erythematosus market report would provide approximately 69 tables, 69 figures and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies